Gestiva Preterm Birth Drug Could Be Approved In October
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA granted a six-month priority review to Adeza’s NDA for the progesterone product under the 505(b)(2) pathway.
You may also be interested in...
KV Purchases Hologic Premature Birth Prevention Candidate; Sale Contingent On FDA Approval
NDA approval is expected in late 2008 for Gestiva, which has been under review since April 2006.
KV Purchases Hologic Premature Birth Prevention Candidate; Sale Contingent On FDA Approval
NDA approval is expected in late 2008 for Gestiva, which has been under review since April 2006.
Adeza’s Gestiva Review To Consider The Validity Of Pivotal Trial’s Primary Endpoint
FDA’s Reproductive Health Drugs Advisory Committee will discuss the preterm birth agent during an Aug. 29 meeting.